A landmark medical breakthrough has emerged after the U.S. Food and Drug Administration approved the first gene therapy designed to treat genetic hearing loss caused by mutations in the OTOF gene, offering new hope to patients born deaf. Developed by Regeneron, the treatment is based on clinical trial results showing that about 90% of participants experienced significant hearing improvement.
